首页> 外文期刊>Bone marrow transplantation >BAT2 and BAT3 polymorphisms as novel genetic risk factors for rejection after HLA-related SCT
【24h】

BAT2 and BAT3 polymorphisms as novel genetic risk factors for rejection after HLA-related SCT

机译:BAT2和BAT3多态性作为抑制HLA相关的SCT后抑制的新型遗传危险因素

获取原文
获取原文并翻译 | 示例
       

摘要

The genetic background of donor and recipient is an important factor determining the outcome of allogeneic hematopoietic SCT (allo-HSCT). We applied whole-genome analysis to investigate genetic variants - other than HLA class I and II - associated with negative outcome after HLA-identical sibling allo-HSCT in a cohort of 110 β-Thalassemic patients. We identified two single-nucleotide polymorphisms (SNPs) in BAT2 (A/G) and BAT3 (T/C) genes, SNP rs11538264 and SNP rs10484558, both located in the HLA class III region, in strong linkage disequilibrium between each other (R2 =0.92). When considered as single SNP, none of them reached a significant association with graft rejection (nominal P0.00001 for BAT2 SNP rs11538264, and P0.0001 for BAT3 SNP rs10484558), whereas the BAT2/BAT3 A/C haplotype was present at significantly higher frequency in patients who rejected as compared to those with functional graft (30.0% vs 2.6%, nominal P=1.15 × 10-8; and adjusted P=0.0071). The BAT2/BAT3 polymorphisms and specifically the A/C haplotype may represent a novel immunogenetic factor associated with graft rejection in patients undergoing allo-HSCT.
机译:供体和受体的遗传背景是确定同种异体造血SCT(Allo-HSCT)的结果的一个重要因素。我们应用全基因组分析以调查遗传变异 - 除了HLA等级I和II之外 - 与110β-Thalassim患者的队列中HLA相同的兄弟杂志-HSCT后的负面结果相关。我们在BAT2(A / g)和BAT3(T / C)基因中,SNP RS11538264和SNP RS10484558中的两个单核苷酸多态性(SNP),位于HLA III级区域中,彼此之间的强烈连锁不平衡(R2 = 0.92)。当被认为是单个SNP时,它们都没有达到与移植物抑制(标称P <0.00001用于BAT2 SNP RS11538264的重要关联,并且对于BAT3 SNP RS10484558的P <0.0001),而BAT2 / BAT3 A / C单倍型在显着更高与功能移植物相比拒绝的患者的频率(30.0%Vs 2.6%,标称P = 1.15×10-8;并调整P = 0.0071)。 BAT2 / BAT3多态性和特异性A / C单倍型可以代表与接受血液HSCT的患者接枝抑制的新型免疫原因因子。

著录项

  • 来源
    《Bone marrow transplantation》 |2014年第11期|共5页
  • 作者单位

    Crs4 BiomedicinePula-(CA) Italy;

    Crs4 BiomedicinePula-(CA) Italy IRGB CNRMonserrato (CA) Italy;

    Laboratory of Immunogenetics and Transplant Biology IME Foundation Polyclinic of Tor Vergata;

    Laboratory of Immunogenetics and Transplant Biology IME Foundation Polyclinic of Tor Vergata;

    International Center for Transplantation in Thalassemia and Sickle Cell Anemia IME Foundation;

    Crs4 BiomedicinePula-(CA) Italy;

    Pediatric Immuno-Hematology Unit and Bone Marrow Transplantation Unit Division of Regenerative;

    Pediatric Immuno-Hematology Unit and Bone Marrow Transplantation Unit Division of Regenerative;

    Centro Trapianti di Midollo Osseo P.O. 'R. Binaghi'Cagliari Italy Department of Hematology;

    Unit of Molecular and Functional Immunogenetics Division of Regenerative Medicine Stem Cells and;

    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) Division of Regenerative Medicine;

    Crs4 BiomedicinePula-(CA) Italy Bioflag SrlPula-(CA) Italy;

    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) Division of Regenerative Medicine;

    San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) Division of Regenerative Medicine;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号